Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: Retrospective study of patient healthcare utilization and symptom burden

Clinical Lung Cancer

Volumn 10, Issue 6, 2009, Pages 426-432

  Stepanski, Edward J ^a   Houts, Arthur C ^a   Schwartzberg, Lee S ^a,b   Walker, Mark S ^a   Reyes, Carolina M ^c,d   Blakely, Johnetta ^a,b  

^a Accelerated Community Oncology Research Network   (United States)

^b WEST CLINIC   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Community oncology; Oral therapy; Patient care monitor; Quality of life; Resource utilization

Indexed keywords

ERLOTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CLINICAL ARTICLE; COMMUNITY; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEALTH CARE UTILIZATION; HOPELESSNESS; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; OUTCOME ASSESSMENT; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; SYMPTOM; THERAPY DELAY; VOMITING; CANCER CENTER; CANCER STAGING; COMMUNITY CARE; DOSE RESPONSE; LUNG TUMOR; MIDDLE AGED; TIME; UTILIZATION REVIEW;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; CARCINOMA, NON-SMALL-CELL LUNG; COMMUNITY HEALTH SERVICES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 74949123098     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.080     Document Type: Article

References (14)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899-909.
3. Non-small-cell lung cancer. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology-v.2.2008. National Comprehensive Cancer Network [Web site]. Available at: http://www.nccn.org/professionals/physician- gls/PDF/nscl.pdf. Accessed: October 16, 2009.
4. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:3238-3247
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132
6. Ramsey SD, Martins RG, Blough DK, et al. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008; 14:297-306.
7. Borner M, Scheithauer W, Twelves C, et al. Answering patients' needs: oral alternatives to intravenous therapy. Oncologist 2001; 6(Suppl 4):12-16
8. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006; 24:3831-3837
9. Herzlinger RE. Cancer care in America: Description and implications of outpatient community-based cancer care. Boston: Boston Healthcare Associates, Inc; 2002.
10. Fortner B, Baldwin S, Schwartzberg L, et al. Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manage 2006; 31:207-214
11. Fortner B, Okon T, Schwartzberg L, et al. The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage 2003; 26:1077-1092
12. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997; 16:2349-2380
13. Littell RC, Pendergast J, Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat Med 2000; 19:1793-1819
14. Ramsey SD, Clarke L, Kamath TV, et al. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J Manag Care Pharm 2006; 12:472-478